Drugs / AMG 357
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02499315 | Apr 2015 → Feb 2016 | rheumatoid arthritis | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT01695876 | Oct 2012 → Sep 2014 | inflammatory disease | Amgen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 357 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01695876 ↗ |
| Modality | Small molecule | “AMG 357 is a small molecule” NCT01695876 ↗ |
| Route | Oral | “Oral administration available in varying dose strength.” NCT01695876 ↗ |